These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 1357544)

  • 1. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
    Morissette M; Lévesque D; Di Paolo T
    Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
    Lévesque D; Di Paolo T
    Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with (-)-stepholidine alters density and turnover of D1 and D2 receptors in striatum.
    Zou LL; Cai ST; Jin GZ
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):485-9. PubMed ID: 9863137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
    Burger LY; Martin-Iverson MT
    Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
    Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
    J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
    Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
    J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum.
    Enz A; Goldstein M; Meller E
    Mol Pharmacol; 1990 Apr; 37(4):560-5. PubMed ID: 1970116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
    Hess EJ; Battaglia G; Norman AB; Creese I
    Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ.
    Neisewander JL; Ong A; McGonigle P
    Synapse; 1995 Feb; 19(2):134-43. PubMed ID: 7725242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term treatment with desipramine increases the turnover of alpha 2-adrenoceptors in the rat brain.
    Barturen F; Garcia-Sevilla JA
    Mol Pharmacol; 1992 Nov; 42(5):846-55. PubMed ID: 1359398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatment with SCH 23390 increases the production rate of dopamine D1 receptors in the nigro-striatal system of the rat.
    Giorgi O; Pibiri MG; Loi R; Corda MG
    Eur J Pharmacol; 1993 Apr; 245(2):139-45. PubMed ID: 8098282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
    Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
    Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of haloperidol on dopamine receptor gene expression.
    Fox CA; Mansour A; Watson SJ
    Exp Neurol; 1994 Dec; 130(2):288-303. PubMed ID: 7867758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Cox RF; Waszczak BL
    Brain Res; 1993 Jun; 613(1):32-42. PubMed ID: 8102308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.